Preclinical CRO Services Global Market Opportunities and Strategies to 2035

This report describes and explains the preclinical CRO services market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global preclinical CRO services market reached a value of nearly $6.24 billion in 2025, having grown at a compound annual growth rate (CAGR) of 10.9% since 2020. The market is expected to grow from $ 6.24 billion in 2025 to $9.94 billion in 2030 at a rate of 9.7%. The market is then expected to grow at a CAGR of 9.1% from 2030 and reach $15.33 billion in 2035.

Growth in the historic period resulted from expansion of clinical trials and robust therapeutic pipeline, increased research and development (R&D) spending in life sciences, expansion of pharmaceutical and biotechnology industries and stringent regulatory and GLP compliance requirements. Factors that negatively affected growth in the historic period were high cost of preclinical studies and limited availability of skilled professionals.

Going forward, expansion of biologics, cell & gene therapy pipelines, growing number of drug candidates requiring IND-enabling studies, growing demand to accelerate time-to-clinic and first-in-human studies and growing reliance on contract research organizations will drive growth. Factors that could hinder the growth of the preclinical CRO services market in the future include regulatory uncertainty and evolving global compliance standards, capacity constraints and skilled workforce shortages and impact of trade war and tariff.

The preclinical CRO services market is segmented by service type into target validation and screening, drug discovery and drug ID, preclinical pharmacology, toxicology and safety assessment, PK/ADME studies, biomarker development and other key service stages. The toxicology and safety assessment market was the largest segment of the preclinical CRO services market segmented by service type, accounting for 26.7% or $1.66 billion of the total in 2025. Going forward, the biomarker development segment is expected to be the fastest growing segment in the preclinical CRO services market segmented by service type, at a CAGR of 11.6% during 2025-2030.

The preclinical CRO services market is segmented by animal model into small animal model and large animal model. The small animal model market was the largest segment of the preclinical CRO services market segmented by animal model, accounting for 72.7% or $4.53 billion of the total in 2025. Going forward, the small animal model segment is expected to be the fastest growing segment in the preclinical CRO services market segmented by animal model, at a CAGR of 10.1% during 2025-2030.

The preclinical CRO services market is segmented by assay type into in-vitro bioassay, in-vivo efficacy assay, pharmacokinetic (PK) assay, ADME assay, toxicology assay and other assay types. The toxicology assay market was the largest segment of the preclinical CRO services market segmented by assay type, accounting for 27% or $1.68 billion of the total in 2025. Going forward, the pharmacokinetic (PK) assay segment is expected to be the fastest growing segment in the preclinical CRO services market segmented by assay type, at a CAGR of 12% during 2025-2030.

The preclinical CRO services market is segmented by disease area into oncology, central nervous system (CNS) disorders, cardiovascular diseases, metabolic disorders, infectious diseases, autoimmune and inflammatory diseases and other disease areas. The oncology market was the largest segment of the preclinical CRO services market segmented by disease area, accounting for 30.3% or $1.89 billion of the total in 2025. Going forward, the oncology segment is expected to be the fastest growing segment in the preclinical CRO services market segmented by disease area, at a CAGR of 11.7% during 2025-2030.

Market-trend-based strategies for the preclinical CRO services market include AI-enabled human-relevant preclinical collaboration advancing predictive research models, expansion into advanced human-relevant preclinical models for precision drug screening, high-throughput ion channel assay development accelerating non-opioid pain drug discovery, strategic expansion into comprehensive oncology preclinical research services and strategic partnerships enhancing high-throughput screening for efficient drug discovery.

The global preclinical CRO services market is fairly concentrated, with large players operating in the market. The top 10 competitors in the market made up 28.46% of the total market in 2024. Charles River Laboratories was the largest competitor with a 3.98% share of the market, followed by Wuxi AppTec Co. Ltd. with 3.89%, Eurofins Scientific SE with 3.85%, Pharmaron Beijing Co Ltd., with 3.80%, Aragen Life Sciences, with 3.63%, Altasciences Inc. with 3.12%, QPS Holdings LLC with 2.49%, Jubilant Biosys Ltd. with 1.86%, Veranex with 1.45% and Kunming Biomed International Ltd. with 0.38%.

The top opportunities in the preclinical CRO services market segmented by service type will arise in the toxicology and safety assessment segment, which will gain $1.13 billion of global annual sales by 2030. The top opportunities in the preclinical CRO services market segmented by animal model will arise in the small animal model segment, which will gain $2.81 billion of global annual sales by 2030. The top opportunities in the preclinical CRO services market segmented by assay type will arise in the toxicology assay segment, which will gain $1.12 billion of global annual sales by 2030. The top opportunities in the preclinical CRO services market segmented by disease area will arise in the oncology segment, which will gain $1.4 billion of global annual sales by 2030. The preclinical CRO services market size will gain the most in the USA at $1.07 billion.

Player-adopted strategies in the preclinical CRO services market include focus on strengthening its business through strategic acquisitions and new launches.

To take advantage of the opportunities, the analyst recommends the preclinical CRO services companies to focus on AI-enabled human-relevant preclinical platforms, focus on advanced human-relevant preclinical models, focus on high-throughput ion channel assays for pain drug discovery, focus on expanding oncology preclinical research services, focus on strategic partnerships to enhance high-throughput screening, focus on biomarker development to drive preclinical CRO growth, focus on pharmacokinetic assays to capture fastest-growing preclinical CRO segment, expand in emerging markets, continue to focus on developed markets, focus on value-based pricing to strengthen market position, focus on digital and scientific thought leadership to enhance visibility, focus on strategic partnerships and industry events to drive client acquisition and focus on oncology to capture the fastest-growing preclinical CRO segment.

This product will be delivered within 3-5 business days.